2020 Galafold Revenue Guidance of $250M-$260M Focused on Pompe Phase 3 PROPEL study and manufacturing to support 2021 BLA and MAA Continued Progress Across Industry Leading Rare Disease Gene Therapy Portfolio Strong Balance Sheet with $450M+ Cash – Cash Runway Well into 2022 CRANBURY, N.J. , Jan.
Galafold Revenue of $181 Million for Full-Year 2019 and $54 Million in Q4 Reflects Continued Strong Adoption & Patient Adherence in All Key Global Regions Galafold Marketing Authorizations Recently Received in Brazil , Colombia and Taiwan Galafold on Track for $500M Revenue by 2023 with Potential
123 Patients Enrolled in Phase 3 PROPEL Study – Enrollment Completed in 4Q2019 Company Plans to Apply for and Initiate a Rolling Biologics License Application (BLA) for AT-GAA in 2020 with Addition of Full Clinical Results in 1H2021 to Support Full Approval under Fast Track Designation Promising
3Q19 Galafold ® (migalastat) Revenue of $48 .8M and 1,000+ Patients on Therapy Reflects Continued Strong Global Uptake Reiterating Upwardly Revised FY19 Revenue Guidance of $170M-$180M Complete Enrollment of 120+ Patients in AT-GAA Pompe Pivotal Study on Track by YE19 Continued
CRANBURY, N.J. , Oct. 30, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Monday, November 11, 2019 at 8:30 a.m. ET to discuss financial results for the third quarter ended September 30, 2019 .
New Data Support Meaningful Impact on Motor and Language Function in Children with Fatal Neurologic Disease Evidence of Disease Stabilization in 7 of 8 Children with Data for up to 2 Years Post-Treatment CRANBURY, N.J. , and CHARLOTTE, N.C. , Oct. 24, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics
Analyst Day 2019 to Highlight Financial Outlook and Robust Portfolio of Novel Therapies for Rare Metabolic Diseases 3Q19 Galafold ® (migalastat) Preliminary Unaudited Revenue of ~$48M+ and 1,000+ Patients on Therapy Reflects Continued Strong Global Uptake Company Raises Lower End of FY19 Global
Persistent and Durable Responses Across Safety, Functional Outcomes and Biomarkers for ERT-Naïve and ERT-Switch Patients in Cohorts 1, 2 and 3 Out to Month 24 Data in Additional Switch Patients (Cohort 4) Consistent with Reponses in Previous Cohorts Demonstrating Improvements in Multiple Measures
CRANBURY, N.J. , Oct. 01, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced upcoming presentations at the following medical and investor conferences in October. Upcoming Medical Conferences: An oral presentation highlighting Phase 1/2 results, including cohort 4, for
CRANBURY, N.J. , Sept. 04, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced upcoming presentations at the following investor conferences in September. Bradley Campbell , President and Chief Operating Officer, and Jeff Castelli , Chief Portfolio Officer and Head of Gene